NFKB1 and psoriasis: CHF6001, a PD4 inhibitor, was reported to repress ROS through inactivating p47 (a subunit of the NOX complex 1) and then inhibit translocation of phosphorylated NF-κB, promoting the loss of cyclin D1 to alleviate redox-inflammatory crosstalk of psoriasis [41].